Fresenius Kabi has announced the availability of Fulvestrant Injection 250mg/5mL prefilled syringe that is stable at room temperature. The product is bioequivalent to Faslodex (AstraZeneca).
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company ...
The FDA has approved label changes for AstraZeneca‘s Faslodex (fulvestrant) injection. Labeling updates include results and a Kaplan-Meier plot of the final overall survival (OS) analysis from CONFIRM ...
(NYSE:AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic ...
Faslodex (fulvestrant) is a prescription medicine used for people with certain types of breast cancer. Faslodex is given as an injection into the buttocks (gluteal area) by a health care provider in a ...
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s fulvestrant formulation has not met the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results